<DOC>
	<DOCNO>NCT00951158</DOCNO>
	<brief_summary>It become apparent many cancer depend specific fat ( lipid ) continue growth . Conjugated linoleic acid ( CLA ) safe , popular , well-tolerated dietary supplement promotes weight loss loss fat . CLA recently show block metabolism ( uptake production ) lipid require growth cancer , result kill cancer cell . The investigator conduct clinical trial test whether oral CLA block metabolism lipids patient advanced cancer . Since dose CLA may yet know , investigator start dose CLA know tolerable effective weight loss . If dose block lipid metabolism , investigator test high dos successive group patient investigator identify effective dose , unless investigator find high dos tolerate . In order verify CLA absorb , necessary measure CLA level blood dos give . Likewise , order verify CLA block lipid metabolism , investigator need obtain small sample abdominal fat ( , patient , sample tumor ) .</brief_summary>
	<brief_title>A Molecular Pharmacodynamic Dose-titration Trial Conjugated Linoleic Acid ( CLA ; Clarinol® ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Written informed consent . 2 . Age 18 year . 3 . Performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Scale . 4 . A predicted life expectancy least 3 month , estimation investigator . 5 . Subjects histologically cytologically confirm advanced solid tumor , fail conventional therapy tumor type tumor type standard effective therapy exists . 6 . At least 4 week since last chemotherapy , radiotherapy , biologic therapy surgery . Subjects must free posttreatment side effect . No concurrent chemotherapy , biologic therapy radiotherapy allow . 7 . Hematological/clinical chemistry criterion : Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,500/mm3 [ ≥ 3.5 x 109/L ] Neutrophils ≥ 1,500/mm3 [ ≥ 1.5 x 109/L ] Platelets ≥ 100,000/mm3 [ ≥ 100.0 x 109/L ] Calculated creatinine clearance ≥60 mL/min use CockcroftGault Formula . 8 . Serum bilirubin &lt; 2.0 mg/dL ( 34 µmol/L ) 9 . SGOT/AST , SGPT/ALT alkaline phosphatase &lt; 2 time upper limit normal liver metastasis visualize abdominal compute tomography ( CT ) magnetic resonance imaging ( MRI scan ) . If liver metastasis present , subject &lt; 5 time upper limit normal eligible participate . 10 . Once RP2D establish , additional patient enrol expand dose cohort must tumor accessible two serial biopsy document ( IHC RTPCR ) express S14 . Exclusion Criteria A subject ineligible follow criterion apply : 1 . Cancer cachexia , define combination : unintentional weight loss ≥10 % , low caloric intake ( ≤ 1500 kcal/day ) , systemic inflammation ( Creactive protein ≥ 10mg/L ) . [ 52 ] 2 . Type II diabetes mellitus 3 . Women pregnant lactating , woman subject childbearing potential refuse practice adequate contraception . ( oral contraceptive IUD ; double barrier diaphragm plus spermicide ; vasectomize partner sterile prior female subject 's entry sole sexual partner female ) . Childbearing potential defined woman surgically sterilize ( i.e . hysterectomy , bilateral oophorectomy [ ovariectomy ] , bilateral tubal ligation ) postmenopausal ( i.e. , document absence menses one year prior entry study ) . 4 . Men unwilling abstain sex use effective contraception study . 5 . Subjects uncontrolled emesis , regardless etiology . 6 . Active infection , seropositivity HIV Hepatitis B/C . 7 . Subjects clinical evidence gastrointestinal ( GI ) condition ( i.e. , removal portion stomach , recent GI obstruction GI neuropathy ) subject take drug would alter GI absorption motility ( e.g. , cisapride ) . 8 . Intercurrent severe medical problem , would significantly limit full compliance study expose subject unnecessary risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Conjugated Linoleic Acid</keyword>
	<keyword>Clarinol</keyword>
	<keyword>S14 Expression</keyword>
</DOC>